Pharvaris NVFRA:9EN -1.76%28 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:9EN with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 731 Biotechnology companies, Pharvaris NV ranks worse than 136798.77% on this metric.
The historical rank and industry rank for Pharvaris NV's Gross Margin % or its related term are showing as below:
FRA:9EN's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Pharvaris NV had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Pharvaris NV was 0.00% per year.
Pharvaris NV (FRA:9EN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pharvaris NV had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pharvaris NV Gross Margin % Related Terms
Pharvaris NV Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pharvaris NV's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9EN vs BHVN, NRIX, VCEL: Gross Margin % Comparison
For the Biotechnology subindustry, Pharvaris NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharvaris NV Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharvaris NV's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pharvaris NV's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pharvaris NV (FRA:9EN) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #999999 out of 731 companies in the Biotechnology industry.
Is Pharvaris NV's Gross Margin % too high?
Pharvaris NV's current Gross Margin % is 0.00%. Based on the distribution chart, Pharvaris NV ranks #999999 out of 731 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Gross Margin % compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #999999 out of 731 companies for Gross Margin %. This places Pharvaris NV in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 731 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Pharvaris NV's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score
Get the complete analysis for FRA:9EN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9EN has been successfully added to your 
